Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for PAS-004 in Neurofibromatosis type 1 (NF1). The expected timing is based on the latest available company guidance and may change.
9/16/25- Activation of 2 South Korean trial sites. 11/4/25– Activated new trial site. 11/21/25– Reported PK data. 01/13/26:- Provide data in H2 2026 including six-month efficacy and safety. 04/01/26:- FDA Fast Track granted for NF1-PN. Phase 1/1b NCT06961565 data still expected H2 2026. 04/20/26:- FDA granted Rare Pediatric Disease Designation for NF1-PN; Ph1/1b NCT06961565 continues. 06/16/26:- Protocol amended; added higher doses and 18-month treatment. Interim NF1 data update still expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.